{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:09:05Z","timestamp":1772431745253,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Testicular germ cell tumors (TGCTs) are highly curable malignancies with long-term overall survival (OS) exceeding 90%. Thromboembolic (TE) events are a relevant treatment-related complication, reported in approximately 10% of patients. This study aimed to evaluate the incidence, risk factors, and prognostic impact of TE in TGCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective multicenter cohort study including 136 post-pubertal male patients with histologically confirmed TGCT treated between 2007 and 2021 at three Portuguese centers. The primary endpoint was to characterize the population of TGCT patients with TE. Secondary endpoints included TE incidence and its impact on OS and progression-free survival (PFS). Identification of clinical, pathological, and treatment-related factors associated with increased TE risk was an exploratory endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven patients (5.1%) developed a TE event, all in advanced\/recurrent disease (14.6% in this subgroup). No TE occurred in stage I patients, including those treated with adjuvant chemotherapy. Visceral metastases (pulmonary and extra-pulmonary) and poor IGCCCG prognosis were associated with TE (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). All TE patients had a central venous catheter (CVC), although only two had catheter-related thrombosis (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.019). For advanced stages, survival outcomes did not differ significantly, with 5-year OS of 71.4% vs. 86.2% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.22) and PFS of 47.6% vs. 75.5% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.23) in TE versus non-TE groups, respectively. Most events (86%) occurred within 30 days of chemotherapy initiation, with pulmonary embolism as the most frequent presentation. Neither the Khorana nor the ONKOTEV scores predicted TE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>TE in TGCT occurred only in patients with advanced disease, was linked to tumor burden and CVC use, and was not predicted by current models. These findings highlight the need for TGCT-specific risk tools and prospective studies on risk-adapted prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1772608","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:20:10Z","timestamp":1772428810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Thromboembolic disease in testicular germ cell tumors\u2014real-world evidence of three Portuguese institutions"],"prefix":"10.3389","volume":"16","author":[{"given":"Joana","family":"Albuquerque","sequence":"first","affiliation":[{"name":"Oncology Department of Hospital da Luz","place":["Lisbon, Portugal"]},{"name":"Cat\u00f3lica University of Medicine, Universidade Cat\u00f3lica Portuguesa","place":["Lisbon, Portugal"]},{"name":"Oncology Department, Hospital da Luz","place":["Set\u00fabal, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martim","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Cat\u00f3lica University of Medicine, Universidade Cat\u00f3lica Portuguesa","place":["Lisbon, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Neto-Silva","sequence":"additional","affiliation":[{"name":"Oncology Department of Unidade Local de Sa\u00fade Loures-Odivelas","place":["Loures, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Margarido","sequence":"additional","affiliation":[{"name":"Oncology Department of Hospital da Luz","place":["Lisbon, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Correia","sequence":"additional","affiliation":[{"name":"Oncology Department of Hospital da Luz","place":["Lisbon, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlota","family":"Baptista","sequence":"additional","affiliation":[{"name":"Oncology Department of Unidade Local de Sa\u00fade Loures-Odivelas","place":["Loures, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalena","family":"Machete","sequence":"additional","affiliation":[{"name":"Oncology Department of Unidade Local de Sa\u00fade Loures-Odivelas","place":["Loures, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Bizarro","sequence":"additional","affiliation":[{"name":"Oncology Department of Unidade Local de Sa\u00fade Loures-Odivelas","place":["Loures, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Rato","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital da Luz","place":["Set\u00fabal, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Godinho","sequence":"additional","affiliation":[{"name":"Oncology Department of Hospital da Luz","place":["Lisbon, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Alberto","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Oncology Department of Unidade Local de Sa\u00fade Loures-Odivelas","place":["Loures, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Passos-Coelho","sequence":"additional","affiliation":[{"name":"Oncology Department of Hospital da Luz","place":["Lisbon, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","unstructured":"Testis SEER 5-year conditional relative survival rates, 2000-2021\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.33999","article-title":"Global patterns in testicular cancer incidence and mortality in 2020","volume":"151","author":"Znaor","year":"2022","journal-title":"Int J Cancer"},{"key":"B3","unstructured":"Cancer stat facts: testicular cancer\n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27122","article-title":"Testicular germ cell tumors","volume":"333","author":"Singla","year":"2025","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472654","article-title":"Key updates in testicular cancer: optimizing survivorship and survival","volume-title":"American society of clinical oncology educational book","author":"Bagrodia","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.euros.2021.07.007","article-title":"Thromboembolic events during treatment with cisplatin-based chemotherapy in metastatic testicular germ-cell cancer 2000\u20132014: A population-based cohort study","volume":"32","author":"Haugnes","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cam4.2674","article-title":"Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)","volume":"9","author":"Tran","year":"2019","journal-title":"Cancer Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e16109","DOI":"10.1200\/jco.2009.27.15_suppl.e16109","article-title":"Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy","volume":"27","author":"Shim","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/10760296211024756","article-title":"Predictors of venous thromboembolism in patients with testicular germ cell tumors: A retrospective study","volume":"27","author":"Abdel\u2010Razeq","year":"2021","journal-title":"Clin Appl Thrombosis\/Hemostasis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3390\/cancers16112082","article-title":"Cancer-associated thrombosis: pathophysiology, laboratory assessment, and current guidelines","volume":"16","author":"Tsantes","year":"2024","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23143","article-title":"Cancer and coagulation","volume":"87","author":"Khorana","year":"2012","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/1471-2407-9-459","article-title":"Thrombosis of abdominal aorta during cisplatin-based chemotherapy of testicular seminoma - a case report","volume":"9","author":"Dieckmann","year":"2009","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12959-018-0161-9","article-title":"Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look","volume":"16","author":"Abdel\u2010Razeq","year":"2018","journal-title":"Thromb J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/j.1538-7836.2007.02788.x","article-title":"Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity","volume":"5","author":"Lechner","year":"2007","journal-title":"J Thromb Haemostasis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0010","article-title":"Validation of the ONKOTEV risk prediction model for venous thromboembolism in outpatients with cancer","volume":"6","author":"Cella","year":"2023","journal-title":"JAMA Network Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2016.10.003","article-title":"Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours","volume":"69","author":"Gizzi","year":"2016","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2021.02.032","article-title":"Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: the european association of urology testicular cancer panel position in 2021","volume":"80","author":"Fankhauser","year":"2021","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.19.01180","article-title":"Cardiovascular risk factors and disease after male germ cell cancer","volume":"38","author":"Lauritsen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2014.60.3654","article-title":"Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: A population-based study","volume":"33","author":"Fung","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"djw265","DOI":"10.1093\/jnci\/djw265","article-title":"Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients","volume":"109","author":"Gonz\u00e1lez\u2010Billalabeitia","year":"2016","journal-title":"JNCI J Natl Cancer Institute"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/cam4.1201","article-title":"Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study","volume":"6","author":"Debourdeau","year":"2017","journal-title":"Cancer Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1772608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:20:11Z","timestamp":1772428811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1772608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1772608"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1772608","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1772608"}}